Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Clovis to Co-develop IVD for Drug Candidate

NEW YORK (GenomeWeb News) – Foundation Medicine and Clovis Oncology today announced a collaboration to develop an in vitro diagnostic test to identify cancer patients who may best respond to a Clovis drug candidate currently in phase I/II clinical development.

The companies will analyze genomic changes in tissue samples from patients in order to assess the possibility of developing an IVD method directed at Clovis' drug rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. Particularly, they said, they aim to identify the additional genetic mutations beyond those in germ-line and somatic BRCA associated with defective DNA repair and that may define tumor targets for rucaparib.

The collaboration may be able to increase the percentage of ovarian cancer patients potentially eligible for rucaparib therapy from 15 percent typically found in germ-line mutations of BRCA to about 40 percent to 50 percent who have DNA repair deficiencies due to somatic mutations in a variety of genes, Foundation and Clovis said.

Financial and other terms of the deal were not disclosed.

Today's deal marks the most recent between Foundation and a pharmaceutical firm in recent months in support of an oncology program, following agreements with Novartis, Array BioPharma, and Sanofi.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.